Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

Arthritis Research & Therapy

Research

Raimon Sanmartí¹  Juan C. Sarmiento-Monroy¹  José A. Gómez-Puerta¹  Eva Perez-Pampin²  Antonio González²  Carmen Conde²  Yolanda Lopez-Golán²  Lorena Rodriguez-Martinez³  Antonio Mera-Varela⁴  María J. Gómara⁵  Isabel Haro⁵  Cristina García-Moreno⁵ 

[1] Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain;Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706, Santiago de Compostela, Spain;Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706, Santiago de Compostela, Spain;Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain;Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706, Santiago de Compostela, Spain;Department of Medicine, Faculty of Medicine, Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain;Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas, (IQAC-CSIC), 08034, Barcelona, Spain;

关键词: Rheumatoid arthritis;    Autoantibodies;    Biomarker;    Post-translational modifications;    Heterogeneity;    Meta-analysis;   

DOI  :  10.1186/s13075-023-03180-x

 received in 2023-05-16, accepted in 2023-09-25,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundAutoantibodies are critical elements in RA pathogenesis and clinical assessment. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies are potentially useful because of their claimed high sensitivity for all RA patients, including those lacking RF and anti-CCP antibodies. Therefore, we aimed to replicate these findings.MethodsWe independently attempted replication in Santiago and Barcelona using sera from 517 and 178 RA patients and 272 and 120 healthy controls, respectively. ELISA protocols for anti-MAA antibodies included five antigens (human serum albumin in three formulations, fibrinogen, and a synthetic peptide) and assays for the IgG, IgM, and IgA isotypes. We integrated our results with information found by searching the Web of Science for reports of anti-MAA antibodies in RA. The available patients (4989 in 11 sets) were included in a meta-analysis aimed at heterogeneity between studies. Factors accounting for heterogeneity were assessed with meta-regression.ResultsThe sensitivity of anti-MAA antibodies in our RA patients was low, even in seropositive patients, with the percentage of positives below 23% for all ELISA conditions. Our results and bibliographic research showed IgG anti-MAA positive patients ranging from 6 to 92%. The extreme between-studies heterogeneity could be explained (up to 43%) in univariate analysis by sex, African ethnicity, the site of study, or recruitment from the military. The best model, including African ancestry and smoking, explained a high heterogeneity fraction (74%).ConclusionAnti-MAA antibody sensitivity is extremely variable between RA patient collections. A substantial fraction of this variability cannot be attributed to ELISA protocols. On the contrary, heterogeneity is determined by complex factors that include African ethnicity, smoking, and sex.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4

Fig. 3